Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis

NCT01387802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 722

Last updated 2020-12-09

No results posted yet for this study

Summary

The current study will assess the real - life effectiveness of adalimumab in the management of Ankylosing Spondylitis (AS) with emphasis on the prevention and management of extra-articular manifestations.

Conditions

Sponsors & Collaborators

  • JSS Medical Research Inc.

    collaborator INDUSTRY
  • Cato Research

    collaborator INDUSTRY
  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-29
Primary Completion
2019-12-16
Completion
2019-12-16

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01387802 on ClinicalTrials.gov